Table 1 Characteristics of patients with 12 (M12) or 24 (M24) months ART experience

Number of patients (n)

19

14

26

43

102

58

103

37

50

37

285

Women (%)

17 (89.5 %)

13 (92.8 %)

20 (76.9 %)

34 (79.1 %)

84 (82.4 %)

42 (72.4 %)

74 (71.9 %)

26 (70.3 %)

39 (78.0 %)

24 (64.9 %)

205 (71.9 %)

Median age years (IQR)

42 (35–51)

38 (36–49)

35 (33–42)

36 (31–40)

36 (31–42)

40 (35–44)

38 (32–45)

40 (34–46)

36 (30–46)

37 (33–42)

39 (33–45)

WHO stages

 1/2

2/19 (10.5 %)

9/14 (64.3 %)

15/24 (62.5 %)

20/42 (47.6 %)

46/99 (46.4 %)

13/58 (22.4 %)

24/102 (23.5 %)

18/34 (52.9 %)

39/43 (90.7 %)

13/37 (35.1 %)

107/274 (39.1 %)

 3/4

17/19 (89.5 %)

5/14 (35.7 %)

9/24 (37.5 %)

22/42 (52.4 %)

53/99 (53.6 %)

45/58 (77.6 %)

78/102 (76.5 %)

16/34 (47.1 %)

4/43 (9.3 %)

24/37 (64.9 %)

167/274 (60.9 %)

CD4 counts available at baseline (n)

18 (94.7 %)

14 (100 %)

26 (100 %)

43 (100 %)

101 (99.0 %)

56/58 (96.6 %)

103/103 (100 %)

31/37 (83.8 %)

42/50 (84 %)

35/37 (94.6 %)

667/285 (93.7 %)

Median CD4 counts at baseline (IQR)

107 (86–181)

109 (71–235)

197 (111–277)

202 (101–274)

176 (86–261)

134 (110–210)

154 (75–232)

120 (80–158)

201 (167–242)

135 (106–185)

152 (88–219)

First line drugs n (%)

 AZT-3TC-EFV

1 (5.3 %)

–

1 (3.8 %)

1 (2.3 %)

3 (2.9 %)

1 (1.7 %)

6 (5.8 %)

2 (5.4 %)

10 (20.0 %)

3 (8.1 %)

23 (8.1 %)

 AZT-3TC-NVP

1 (5.3 %)

–

10 (23.3 %)

11 (10.8 %)

7 (12.1 %)

–

–

6 (12.0 %)

–

13 (4.6 %)

 AZT-3TC-NVP/EFV

–

–

–

–

–

–

2 (1.9 %)

–

–

–

2 (0.7 %)

 D4T-3TC-NVP

1 (5.3 %)

5 (35.7 %)

7 (26.9 %)

2 (4.7 %)

15 (14.7 %)

4 (6.9 %)

3 (2.9 %)

–

1 (2.0 %)

1 (2.7 %)

9 (3.2 %)

 D4T/AZT-3TC-NVP

16 (84.2 %)

7 (20.0)

15 (57.7 %)

28 (65.1 %)

66 (64.7 %)

43 (75.8 %)

86 (83.5 %)

32 (86.5 %)

32 (64.0 %)

33 (89.2 %)

226 (79.3 %)

 D4T/AZT-3TC-NVP/EFV

–

2 (10.0 %)

1 (3.8 %)

3 (2.9 %)

3 (5.2 %)

1 (0.98 %)

3 (8.1 %)

–

–

7 (2.5 %)

 D4T/AZT/TDF-3TC-NVP/EFV

–

–

1 (3.8 %)

1 (2.3 %)

2 (1.9 %)

–

2 (1.9 %)

–

–

–

2 (0.7 %)

 TDF-3TC-AZT

–

–

–

–

–

–

1 (0.98 %)

–

–

–

1 (0.3 %)

 TDF-3TC-NVP

–

–

1 (3.8 %)

–

1 (0.99 %)

–

–

–

–

–

–

 AZT/TDF-3TC-NVP/EFV

–

–

–

1 (2.3 %)

1 (0.99 %)

–

–

–

–

–

–

 D4T/AZT/TDF-3TC-EFV

–

–

–

–

–

–

1 (0.98 %)

–

–

–

1 (0.3 %)

 AZT/TDF-3TC-EFV

–

–

–

–

–

–

1 (0.98 %)

–

–

–

1 (0.3 %)

 VL >1000 copies/ml n (%)

6/19 (31.6 %)

3/14 (23.1 %)

5/26 (19.2 %)

6/43 (13.9 %)

20/102 (19.6 %)

13/58 (22.4 %)

14/103 (13.6 %)

11/37 (29.7 %)

9/50 (18.0 %)

3/37 (8.1 %)

50/285 (17.5 %)

 Obtained pol sequences (n/n tested)

6/6

3/3

5/5

6/6

20/20

12/13

14/14

10/11

8/9

3/3

47/50

 Frequency of drug resistant HIV (n/n tested)

6/6

3/3

5/5

6/6

20/20

12/12

13/14

10/10

7/8

3/3

45/47

 NRTI only

0

0

0

0

0/20

0

0

1

1

0

2

 NNRTI only

0

0

0

0

0/20

3

1

0

0

0

4

 NRTI + NNRTI

6

3

5

6

20/20

9

12

9

6

3

39

 Global drug resistance n (%)

6/19 (31.6 %)

3/14 (23.1 %)

5/26 (19.2 %)

6/43 (13.9 %)

20/102 (19.6 %)

12/58 (20.7 %)

13/103 (12.6 %)

10/37 (27.0 %)

7/50 (14.0 %)

3/37 (8.1 %)

45/285 (15.8 %)

 Resistance to 2 drugs of first line ART

4

3

3

2

12/20

2

6

5

2

0

15/45

 Resistance to 3 drugs of first line ART

2

0

2

4

8/20

7

6

5

4

3

25/45

Cross-resistance to second line NNRTI

 ETV

1

0

1

1

3/20

3

3

3

1

1

11/45

 RPV

3

1

3

6

13/20

9

8

6

5

3

31/45

Cross-resistance to other NRTIs

 ABC

2(I)

0

2

1

3/20

2

1

3

1

2

9/45

 DDI

0

0

1

0

1/20

2

0

0

0

0

2/45

 TDF

0

0

1

0

1/20

1

1

0

0

0

2/45